Nicox S.A., the international ophthalmic R&D company, today announced its financial results for the six months ended June 30, 2016, and provided an update on its activities.

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced its financial results for the six months ended June 30, 2016, and provided an update on its activities.
“Following the recently completed transaction with GHO Capital involving our European and International commercial assets, we are now well positioned to refocus our resources on our promising R&D pipeline as we await FDA approval decisions for latanoprostene bunod and AC-170,” commented Michele Garufi, Chairman and Chief Executive Officer of Nicox. “This transaction allows us to reduce our infrastructure costs by €6 million (approximately 66%) and, together with the recent financing of €18 million, to accelerate the development of our proprietary pipeline assets, including obtaining clinical proof-of-concept data for NCX 4251 and NCX 470 by the end of 2018.”
Operational highlights for the six months to June 30, 2016 and post-reporting period

  • In August 2016, Nicox completed the transfer of its European and International commercial operations to a new pan-European ophthalmic specialty pharmaceutical company led by GHO Capital. The transaction was valued at up to €26 million and the Company received a €9 million upfront cash payment upon closing of the transaction and a minority stake in the new company.
  • In July 2016, Nicox completed a financing through a reserved capital increase of ordinary shares of the Company with a specific category of investors. Gross proceeds from the financing were €18 million.
  • On July 21, 2016, latanoprostene bunod licensee Bausch + Lomb (a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.) announced its receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the use of latanoprostene bunod for the treatment of glaucoma. The CRL cited concerns pertaining to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb’s manufacturing facility in Tampa, Florida. The FDA’s letter did not identify any efficacy or safety concerns with respect to the latanoprostene bunod NDA or additional clinical trials needed for the approval of the NDA. Bausch + Lomb is currently working with the FDA to resolve and address the CGMP concerns. Latanoprostene bunod has the potential to generate significant revenue for Nicox through milestones (up to $132.5 million net, mainly on commercial sales targets) and royalties (potential net tiered royalties on sales from 6% to 11%).
  • In June, Nicox announced that the U.S. FDA had accepted the Company’s NDA for AC-170, a novel, proprietary eye drop formulation of cetirizine, targeting the treatment of ocular itching associated with allergic conjunctivitis. The FDA also granted Priority Review and assigned a Prescription Drug User Fee (PDUFA) goal date of October 18, 2016 (contingent upon the information and data provided by Nicox during the review period). Approval of the AC-170 NDA prior to December 1st, 2016 will trigger a milestone payment of $35 million in Nicox shares to former Aciex shareholders or $10 million in Nicox shares if approval of the NDA is received after this date. Nicox is currently in partnering discussions in the United States for this program.

Other Updates

  • Philippe Masquida, EVP, Managing Director European & International Operations, will be leaving the company at the end of September 2016, following the successful completion of the transfer of the European and International commercial operations. Nicox sincerely thanks Philippe for his years of service and his significant contributions to the commercial business.

First-half financial summary2

The Group’s revenues have been retreated following reclassification of the European commercial business as Discontinued Operations. For information, the European and International product sales of the operations transferred to VISUfarma BV, the new Group led by GHO Capital, were €7.1 million over the first half of 2016, an increase of 50% compared to the same period in 2015.
Excluding Discontinued Operations the operating expenses for the period were €12.0 million compared to €8.8 million for the six months to June 2015. The increase in operating expenses over the period is mainly explained by costs related to the submission of the AC-170 NDA.
Excluding the Discontinued Operations, the Group recorded a net loss of €12.3 million as of June 2016, compared to a net loss of €10.1 million3 at the same date in 2015.
The Group had cash, cash equivalents and financial instruments of €12.3 million as of June 30, 2016, compared to €29 million on December 31, 2015; however, considering the financing in July of this year of €18 million gross and the €8.9 million cash payment following the transfer of the European commercial operations to VISUfarma BV, our unaudited cash, cash equivalents and financial instruments at August 31, 2016 are estimated at €34.1 million.
The half-yearly financial report will be available in French by the end of September 2016 on Nicox’s website in the section Investor Information > Regulated information > Financial Information.
The procedures relating to the limited review of the interim financial statements have been carried out. The limited review report will be issued after the finalisation of the procedures required for the publication of the-first half financial report.
1 Unaudited cash, cash equivalents and financial instruments at August 31, 2016.
2 Revenues, costs, assets and liabilities for the European commercial operations are treated as “Discontinued Operations” in accordance with IFRS 5
3 The net loss for H1 2015 has been adjusted to remove the European commercial operations.
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international R&D company focused on the ophthalmic market. For more information on Nicox, its products or pipeline, please visit:
Analyst coverage

Bryan, Garnier & CoHugo SolvetParis, France
Invest SecuritiesMartial DescouturesParis, France
Gilbert DupontDamien ChoplainParis, France
StifelMax HermannLondon, UK


Upcoming financial and business conferences

October 5-6Large & Midcap EventParis, France
November 15-16Stifel 2016 Healthcare ConferenceNew York, US
November 18-19ActionnariaParis, France
November 21-23Deutsches EigenkapitalforumFrankfurt, Germany
December 13Guggenheim Securities 4th Annual Boston Healthcare ConferenceBoston, US


Nicox  Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 |
Media Relations   
United Kingdom  Jonathan Birt
Tel +44 7860 361 746 |
France  NewCap | Nicolas Merigeau
Tel +33 (0)1 44 71 94 98 |
United States  Argot Partners | Eliza Schleifstein
Tel +1 (917) 763-8106 |
Investor Relations   
Europe  NewCap | Julien Perez | Valentine Brouchot
Tel +33 (0)1 44 71 94 94 |
United States  Argot Partners | Melissa Forst
Tel +1 (212) 600-1902 |

The information contained in this document may be modified without former notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Consolidated statement of Comprehensive Income – June 30, 2016

As of June 30,
201622015 restated3,4
(in thousands of € except for per share data)
Cost of sales(2)
Gross margin977
Selling expenses(97)(1,154)
General and administrative expenses(4,376)(4,731)
Research and development expenses(6,544)(2,288)
Other operating income284448
Other operating expense(981)(616)
Total operations loss before fair value changes of contingent consideration and impairment of intangible assets(11,706)(8,264)
Fair value changes of contingent considerations(995)(2,576)
Impairment of intangible assets
Operating loss(12,702)(10,840)
Finance income54986
Finance costs(241)(487)
Net finance revenues(186)509
Loss before tax(12,888)(10,331)
Income tax(18)(10)
Loss from continuing operations(12,906)(10,341)
Loss from discontinued operations(11,307)(5,431)
Net loss of the year(24,213)(15,772)
Attributable to owners of the Compagny(24,213)(15,772)
Total comprehensive income (loss) for the period, net of tax (€/share)(1,06)(0,72)
Basic/diluted earnings per share from continuing operations (€/share)(0,56)(0,47)
Basic/diluted earnings per share from discontinued operations (€/share)(0,49)(0,25)

2 Revenues, costs, assets and liabilities for the European commercial operations are treated as “Discontinued operations” in accordance with IFRS 5

3 The net loss for H1 2015 has been adjusted to remove the European commercial operations.

4 For a greater clarity of the Group performance, the presentation of the consolidated statement of comprehensive income has been modified. Lines, gross margin, fair value of changes of contingent considerations and impairment of intangible assets have been created.

consolidated Statement of Financial Position – June 30, 2016

As of June 30th, 2016As of December 31st, 2015
(in thousands of €)
Non-current assets
Intangible assets73,68892,141
Property, plant and equipmenta262866
Other investments, including derivatives184253
Total non-current assets100,288125,505
Current assets 
Trade receivables423,027
Subsidies receivables813727
Other receivables9753,013
Other current assets, including derivatives532
Cash and cash equivalents12,34229,070
Assets held for sales24 524
Total current assets 39,47537,843
TOTAL ASSETS139,763163,348
Equity attributable to equity holders of the parent
Share capital22,89922,870
Premium related to share capital469,089469,119
Currency translation adjustment8,68810,049
Tresury shares(355)(458)
Consolidates reserves(397,471)(372,310)
Net income/(loss)(24,213)(27,939)
Total Equity78,622101,331
Non-current liabilities
Non-current financial debts391,567
Non-current liabilites related to business combination1,4012,066
Deferred tax liabilites27,92330,759
Non-current provisions448617
Total non-current liabilities29,81135,009
Current liabilities 
Current financial debts40308
Current liabilites related to business combination18,48116,832
Trade payables1,9165,364
Deferred income/revenue22
Other current liabilities(2,513)4,502
Liabilities directly associated with the assets held for sales8,378
Total current liabilities31,32927,008

2 Revenues, costs, assets and liabilities for the European commercial operations are treated as “Discontinued operations” in accordance with IFRS 5



S&P 5003818.83-2.72


Heating Oil3.91-0.04
Natural Gas6.500.00